Rock Springs Capital logo

Rock Springs Capital

North America, Maryland, United States, Baltimore

Description

Rock Springs Capital is an investment company specializing on managing security portfolios and providing portfolio management solutions.

Investor Profile

Rock Springs Capital has backed more than 147 startups, with 5 new investments in the last 12 months alone. The firm has led 10 rounds, about 7% of its total and boasts 96 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Post Ipo Equity rounds (top funding stages).
  • Majority of deals are located in United States, United Kingdom, China.
  • Strong thematic focus on Biotechnology, Health Care, Medical.

Stage Focus

  • Series B (28%)
  • Series C (24%)
  • Post Ipo Equity (17%)
  • Series A (8%)
  • Series D (7%)
  • Series E (6%)
  • Series Unknown (5%)
  • Private Equity (3%)
  • Series F (1%)
  • Debt Financing (1%)

Country Focus

  • United States (86%)
  • United Kingdom (5%)
  • China (3%)
  • Canada (2%)
  • Germany (1%)
  • Singapore (1%)
  • Switzerland (1%)
  • The Netherlands (1%)
  • Denmark (1%)
  • France (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Biopharma
  • Life Science
  • Oncology
  • Health Diagnostics
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Rock Springs Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 29
Sofinnova Investments
North America, California, United States, Menlo Park
Co-Investments: 17
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 16
CA
North America, Massachusetts, United States, Boston
Co-Investments: 25
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 18
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 27
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 23
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 38
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 24
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 19

Which angels does Rock Springs Capital often collaborate with?

CI
North America, New York, United States, New York
Shared Deals: 1
PH
North America, Nebraska, United States, Omaha
Shared Deals: 1
Shared Deals: 2
AG
North America, New Jersey, United States, New Brunswick
Shared Deals: 1
JR
North America, California, United States, San Francisco
Shared Deals: 1
SS
North America, California, United States, Los Angeles
Shared Deals: 2
LH
North America, Nebraska, United States, Omaha
Shared Deals: 1
GB
Europe, England, United Kingdom, London
Shared Deals: 2
ML
North America, California, United States, Portola Valley
Shared Deals: 1
Daphne Teo
Asia, Singapore
Shared Deals: 1

What are some of recent deals done by Rock Springs Capital?

Avalyn Pharma

Seattle, Washington, United States

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series DJul 22, 2025
Amount Raised: $100,000,000
Latigo Biotherapeutics

Thousand Oaks, California, United States

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

BiotechnologyHealth CareMedicalTherapeutics
Series BMar 17, 2025
Amount Raised: $150,000,000
Aclaris Therapeutics

Malvern, Pennsylvania, United States

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

BiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityNov 18, 2024
Amount Raised: $80,000,000
City Therapeutics

Cambridge, Massachusetts, United States

City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.

BiopharmaLife ScienceTherapeutics
Series AOct 8, 2024
Amount Raised: $135,000,000
ArsenalBio

South San Francisco, California, United States

ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors.

BiotechnologyCloud ComputingLife ScienceMedical
Series CSep 4, 2024
Amount Raised: $325,000,000
Imperative Care

Campbell, California, United States

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health CareMedicalMedical Device
Series EJul 25, 2024
Amount Raised: $150,000,000
Mereo Biopharma

London, England, United Kingdom

Mereo is a new UK-based speciality biopharmaceutical company.

BiopharmaBiotechnologyHealth CareInnovation Management
Post Ipo EquityJun 14, 2024
Amount Raised: $50,000,000
Zenas BioPharma

Waltham, Massachusetts, United States

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

BiopharmaHealth CarePharmaceutical
Series CMay 7, 2024
Amount Raised: $200,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityApr 18, 2024
Amount Raised: $70,000,000
Cullinan Therapeutics

Cambridge, Massachusetts, United States

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

BiopharmaBiotechnologyMedical DeviceOncology
Post Ipo EquityApr 16, 2024
Amount Raised: $280,000,000